The clinical value of p53 and the parameters of DNA-flow cytofluorometry in combination with clinical and morphological predictors in breast cancer
https://doi.org/10.17650/1994-4098-2010-0-2-44-46
Abstract
The determination of mutant p53 and the basic parameters studied by DNA-flow cytofluorometry in combination with other clinical and morphological predictors may be used as additional prognostic criteria individually in each patient with breast cancer.
About the Authors
L. K. Tsoi
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. N. Bogatyrev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
V. P. Letyagin
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
Ya. V. Vishnevskaya
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. M. Platova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Аксель Е.М., Давыдов М.И. Статистика злокачественных новообразований молочных желез. В сб.: Лекции по маммологии. М.: МЕДпресс-информ, 2009. с. 9–16.
2. Божок А.А., Семиглазов В.Ф., Семиглазов В.В. и др. Факторы прогноза при раке молочной железы. СПб., 2006. www.RosOncoWeb
3. Боядзис М.М., Лубоуиц П.Ф., Фрейм Д.Н. Краткое руководство по лечению опухолевых заболеваний. М.: Практическая медицина, 2009. с. 325–93.
4. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2006. Вестн РОНЦ им. Н.Н. Блохина 2008;19:52–70.
5. Kelloff G.J., Lippman S.M., Danneberg A.J. et al. Progress in chemoprevention drug development: Тhe promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer – a plan to move forward. Clin Cancer Res 2006; 12(12):3661–1697.
6. . Lombardo J.F. Molecular prediction of recurrence of breast cancer (author reply). N Engl J Med 2005;353:1300.
7. Paik S., Bryant J., Tan-Chiu E. et al. Real-world performance of Her-2 testing – national surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002;94:852–4.
8. Чен У.И., Уордли Э. Рак молочной железы. Рид Элсивер, 2009. с. 89–103.
9. Page D.L, Gray R., Allred D.C. et al. Prediction of nodenegative breast cancer outcome by histologic grading and S-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192). Am J Clin Oncol 2001;24:10–8.
10. Skliris G., Parkes A., Limer J. et al. Evaluation of seven oestrogen receptor b antibodies for immunohistochemistry, western blotting and flow cytometry in humanbreast tissue. J Pathol 2002;197:155–62.
11. Летягин В.П. Опухоли молочных желез. М.: Практическая медицина, 2007. с. 87–91.
12. Hayes D.F. Tumor markers for breast cancer. Ann Oncol 2003;4:807–19.
13. Van den Brandt P.A., Spiegelman D., Yann S.S. et al. Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 2000;152 (6): 514–27.
Review
For citations:
Tsoi L.K., Bogatyrev V.N., Letyagin V.P., Vishnevskaya Ya.V., Platova A.M. The clinical value of p53 and the parameters of DNA-flow cytofluorometry in combination with clinical and morphological predictors in breast cancer. Tumors of female reproductive system. 2010;(2):44-46. (In Russ.) https://doi.org/10.17650/1994-4098-2010-0-2-44-46
Views:
532
Email this article 